<DOC>
	<DOCNO>NCT02444936</DOCNO>
	<brief_summary>This study evaluate shingle vaccine work person receive receive chemotherapy solid organ tumor . Half participant receive ZOSTAVAX shingle vaccine half participant receive anything .</brief_summary>
	<brief_title>ZOSTAVAX Persons Imminently Receiving Chemotherapy Solid Organ Tumors</brief_title>
	<detailed_description>This study single blind randomize clinical trial measure immunologic efficacy ZOSTAVAX vs. vaccine 60 adult solid organ tumor , chemotherapy . The personnel perform laboratory study blind vaccine vs. vaccine . In pilot study FDA approve vaccine use within parameter package insert ACIP recommendation , placebo vaccine require access key primary immunologic endpoint .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Solid organ tumor patient least 14 day entry study ZOSTAVAX vaccination initial therapy malignancy include chemotherapy alone surgery subsequent chemotherapy plus minus radiation therapy A plan chemotherapy onset least anticipated stop date within 36 month sample collection phase study Prior history HZ shingle vaccine Systemic chemotherapy &lt; 3 month prior enrollment Any history hematologic malignancy , HIV/AIDS , hematopoietic stem cell transplant , cellular immunodeficiency state Those receive immunomodulating drug time vaccination prednisone methotrexate , azathioprine , mercaptopurine , biologics include TNFalpha inhibitor Widespread metastatic tumor bone marrow involvement Indefinite duration palliative chemotherapy subject Inability communicate study staff bring unable consent History anaphylactic/anaphylactiod reaction gelatin , neomycin , component vaccine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>vaccine</keyword>
</DOC>